148 citations
,
April 2018 in “Environmental Research” This study found that hair products used by Black women and children in the U.S. contain multiple chemicals associated with endocrine disruption and asthma, highlighting potential exposure disparities and a need for improved labeling.
April 2023 in “Journal of Dermatological Treatment” This study observed a significant reduction in the number of hair follicles with a high proportion in catagen or telogen phase, along with visible vertical columns of connective tissue in the histopathologic examination.
1 citations
,
September 2025 in “PLOS Digital Health” This study found that all four evaluated large language models generated a significant proportion of inappropriate responses when prompted with or without LGBTQIA+ identity terms, with more severe bias observed in prompts mentioning LGBTQIA+ identities.
January 2024 in “American journal of clinical dermatology” This study reports that ritlecitinib, when used for up to 24 months in patients aged 12 and older with alopecia areata, has an acceptable safety profile, with a similar proportion of adverse events in both ritlecitinib and placebo groups in the placebo-controlled cohort.
July 2018 in “Elsevier eBooks” This review discusses telogen effluvium, a common form of hair loss, and reports no new clinical results; the authors outline possible causes, typical prognosis, and management strategies.